Targeting SGK1 may be a therapeutic option in several clinical conditions, including metabolic syndrome and tumor growth.
No takes yet. Share an insight, caveat, or question.
Läng et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: